Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-21), ZYUS Life Sciences's 12-1 Month Momentum % is -97.91%.
The industry rank for ZYUS Life Sciences's 12-1 Month Momentum % or its related term are showing as below:
ZLSCF's 12-1 Month Momentum % is ranked worse than 99.31% of 1016
companies
in the Drug Manufacturers industry
Industry Median: -12.415
vs ZLSCF: -97.91
ZYUS Life Sciences (OTCPK:ZLSCF) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ZYUS Life Sciences 12-1 Month Momentum % Related Terms
ZLSCF vs SKYI, CBDY, NPHC: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's 12-1 Month Momentum % falls into.
ZYUS Life Sciences (OTCPK:ZLSCF) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -97.91% mean?
ZYUS Life Sciences (ZLSCF) has a 12-1 Month Momentum % of -97.91% as of Sep. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #1009 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 99.3%.
Is ZYUS Life Sciences' 12-1 Month Momentum % too high?
ZYUS Life Sciences' current 12-1 Month Momentum % is -97.91%. Based on the distribution chart, ZYUS Life Sciences ranks #1009 out of 1016 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' 12-1 Month Momentum % compare to SKYI and CBDY?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #1009 out of 1016 companies for 12-1 Month Momentum %. This places ZYUS Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current 12-1 Month Momentum % is -97.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Fairly Valued. The stock's GF Value™ is $0.55, compared to a current price of $0.60 — trading 9.1% above its estimated fair value. The current 12-1 Month Momentum % is -97.91%. ZYUS Life Sciences' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current 12-1 Month Momentum % is -97.91% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?
Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued.
The current stock price of $0.60 is trading 9.1% above its estimated GF Value™ of $0.55.
GuruFocus considers ZYUS Life Sciences to be Fairly Valued.
Key valuation signals for ZLSCF:
12-1 Month Momentum %: -97.91%
GF Value™: $0.55 vs. price of $0.60 (9.1% above fair value)
No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score
Get the complete analysis for ZLSCF
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLSCF has been successfully added to your 
